Detection of drug-induced acute respiratory distress syndrome risk signals in FAERS: a real-world pharmacovigilance study - Top-Institutions - MDSpire

Detection of drug-induced acute respiratory distress syndrome risk signals in FAERS: a real-world pharmacovigilance study

  • By

  • Yunhan Zhao

  • Feiyang Zhao

  • Haoxiang Hu

  • Jianghai He

  • Yiting Ni

  • Pingping Jin

  • Xiao Wang

  • Zheru Jin

  • Yiren Hu

  • June 11, 2026

  • 0 min

Share

Top Institutions in Pulmonary

Brief introduction explaining scope and methodology.

  • #1

    Massachusetts General Hospital
    Massachusetts General Hospital

    Boston, Massachusetts

    Key Differentiators

    • Pharmacology
    • Critical Care

  • #2

    Brigham and Women’s Hospital
    Brigham and Women’s Hospital

    Boston, Massachusetts

    Key Differentiators

    • Pharmacology
    • Critical Care

  • #3

    NeuroDeRisk consortium
    NeuroDeRisk consortium

    N/A, N/A

    Key Differentiators

    • Pharmacology

  • #4

    Observational Medical Outcomes Partnership
    Observational Medical Outcomes Partnership

    N/A, N/A

    Key Differentiators

    • Pharmacology

  • #5

    Uppsala Monitoring Centre
    Uppsala Monitoring Centre

    Uppsala, Sweden

    Key Differentiators

    • Pharmacology

Original Source(s)

Detection of drug-induced acute respiratory distress syndrome risk signals in FAERS: a real-world pharmacovigilance study

  • by Yunhan Zhao, Feiyang Zhao, Haoxiang Hu, Jianghai He, Yiting Ni, Pingping Jin, Xiao Wang, Zheru Jin, Yiren Hu

  • June 11, 2026

Related Content

Metabolic biomarkers differentiate extrapulmonary tuberculosis from pulmonary TB and non-TB pleural effusions

CXCR3 ameliorates neutrophil-dependent disease severity in SARS-CoV-2 infection by regulating CD4+ T cell recruitment

Relapsing allergic bronchopulmonary aspergillosis as a trigger for Kounis syndrome: a case report